Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Control of Chronic Mycobacterium tuberculosis Infection by CD4 KLRG1− IL-2–Secreting Central Memory Cells
Thomas Lindenstrøm, Niels Peter Hell Knudsen, Else Marie Agger, et al.
The Journal of Immunology (2013) Vol. 190, Iss. 12, pp. 6311-6319
Open Access | Times Cited: 160

Showing 1-25 of 160 citing articles:

A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis-specific T-cell responses in human
Jaap T. van Dissel, Simone A. Joosten, Søren T. Hoff, et al.
Vaccine (2014) Vol. 32, Iss. 52, pp. 7098-7107
Open Access | Times Cited: 220
Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens
Niels Peter Hell Knudsen, Anja Weinreich Olsen, Cecilia Buonsanti, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 218
Controlling timing and location in vaccines
Darrell J. Irvine, Aereas Aung, Murillo Silva
Advanced Drug Delivery Reviews (2020) Vol. 158, pp. 91-115
Open Access | Times Cited: 203
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
Angelique Kany Kany Luabeya, Benjamin M. Kagina, Michèle Tameris, et al.
Vaccine (2015) Vol. 33, Iss. 33, pp. 4130-4140
Closed Access | Times Cited: 179
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trial
François Spertini, R Audran, Reza Chakour, et al.
The Lancet Respiratory Medicine (2015) Vol. 3, Iss. 12, pp. 953-962
Open Access | Times Cited: 162
Polyfunctional CD4+ T Cells As Targets for Tuberculosis Vaccination
David Lewinsohn, David Lewinsohn, Thomas J. Scriba
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 161
Antigen Availability Shapes T Cell Differentiation and Function during Tuberculosis
Albanus O. Moguche, Munyaradzi Musvosvi, Adam Penn‐Nicholson, et al.
Cell Host & Microbe (2017) Vol. 21, Iss. 6, pp. 695-706.e5
Open Access | Times Cited: 160
The Recombinant Bacille Calmette–Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing
Natalie E. Nieuwenhuizen, Prasad S. Kulkarni, Umesh Shaligram, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 153
Novel Vaccination Strategies against Tuberculosis
Peter Andersen, Stefan H. E. Kaufmann
Cold Spring Harbor Perspectives in Medicine (2014) Vol. 4, Iss. 6, pp. a018523-a018523
Open Access | Times Cited: 147
Moving tuberculosis vaccines from theory to practice
Peter Andersen, Thomas J. Scriba
Nature reviews. Immunology (2019) Vol. 19, Iss. 9, pp. 550-562
Open Access | Times Cited: 136
ICOS and Bcl6-dependent pathways maintain a CD4 T cell population with memory-like properties during tuberculosis
Albanus O. Moguche, Shahin Shafiani, Corey Clemons, et al.
The Journal of Experimental Medicine (2015) Vol. 212, Iss. 5, pp. 715-728
Open Access | Times Cited: 133
Next-Generation Vaccines Based on Bacille Calmette–Guérin
Natalie E. Nieuwenhuizen, Stefan H. E. Kaufmann
Frontiers in Immunology (2018) Vol. 9
Open Access | Times Cited: 116
Central Memory CD4+ T Cells Are Responsible for the Recombinant Bacillus Calmette-Guérin ΔureC::hly Vaccine's Superior Protection Against Tuberculosis
Alexis Vogelzang, Carolina Perdomo, Ulrike Zedler, et al.
The Journal of Infectious Diseases (2014) Vol. 210, Iss. 12, pp. 1928-1937
Open Access | Times Cited: 114
Tuberculosis vaccines – rethinking the current paradigm
Peter Andersen, Joshua S. Woodworth
Trends in Immunology (2014) Vol. 35, Iss. 8, pp. 387-395
Closed Access | Times Cited: 108
Subunit vaccine H56/CAF01 induces a population of circulating CD4 T cells that traffic into the Mycobacterium tuberculosis-infected lung
Joshua S. Woodworth, Sara Cohen, Albanus O. Moguche, et al.
Mucosal Immunology (2016) Vol. 10, Iss. 2, pp. 555-564
Open Access | Times Cited: 106
Defining features of protective CD4 T cell responses to Mycobacterium tuberculosis
Shunsuke Sakai, Katrin D. Mayer‐Barber, Daniel L. Barber
Current Opinion in Immunology (2014) Vol. 29, pp. 137-142
Open Access | Times Cited: 102
The Immune Response toMycobacterium tuberculosisin HIV-1-Coinfected Persons
Hanif Esmail, Catherine Riou, Elsa Du Bruyn, et al.
Annual Review of Immunology (2018) Vol. 36, Iss. 1, pp. 603-638
Open Access | Times Cited: 102
Th1 Differentiation Drives the Accumulation of Intravascular, Non-protective CD4 T Cells during Tuberculosis
Michelle A. Sallin, Shunsuke Sakai, Keith D. Kauffman, et al.
Cell Reports (2017) Vol. 18, Iss. 13, pp. 3091-3104
Open Access | Times Cited: 99
Tuberculosis Vaccine Development: Progress in Clinical Evaluation
Suraj B. Sable, James E. Posey, Thomas J. Scriba
Clinical Microbiology Reviews (2019) Vol. 33, Iss. 1
Open Access | Times Cited: 92
Dose Optimization of H56:IC31 Vaccine for Tuberculosis-Endemic Populations. A Double-Blind, Placebo-controlled, Dose-Selection Trial
Sara Suliman, Angelique Kany Kany Luabeya, Hennie Geldenhuys, et al.
American Journal of Respiratory and Critical Care Medicine (2018) Vol. 199, Iss. 2, pp. 220-231
Closed Access | Times Cited: 88
Immunocorrelates of CAF family adjuvants
Gabriel Kristian Pedersen, Peter Andersen, Dennis Christensen
Seminars in Immunology (2018) Vol. 39, pp. 4-13
Open Access | Times Cited: 83
T-cell exhaustion in tuberculosis: pitfalls and prospects
Nargis Khan, Aurobind Vidyarthi, Mohammed Amir, et al.
Critical Reviews in Microbiology (2016) Vol. 43, Iss. 2, pp. 133-141
Closed Access | Times Cited: 80
The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial
Hennie Geldenhuys, Helen Mearns, David J. C. Miles, et al.
Vaccine (2015) Vol. 33, Iss. 30, pp. 3592-3599
Closed Access | Times Cited: 76
Delta inulin-based adjuvants promote the generation of polyfunctional CD4+ T cell responses and protection against Mycobacterium tuberculosis infection
Claudio Counoupas, Rachel Pinto, Gayathri Nagalingam, et al.
Scientific Reports (2017) Vol. 7, Iss. 1
Open Access | Times Cited: 73
Enhanced protection conferred by mucosal BCG vaccination associates with presence of antigen-specific lung tissue-resident PD-1+ KLRG1− CD4+ T cells
Naomi Bull, Elena Stylianou, Daryan A. Kaveh, et al.
Mucosal Immunology (2018) Vol. 12, Iss. 2, pp. 555-564
Open Access | Times Cited: 70
Page 1 - Next Page

Scroll to top